ANDA 211175, held by Fougera Pharms Inc. Tazarotene.
As of Nov 15, 2026, ANDA 211175 (Tazarotene), held by Fougera Pharms Inc, was first approved by FDA on Jan 28, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tazarotene0.1% ยท cream;topical | Tazarotene | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
